| Name | Title | Contact Details |
|---|
Copernicus is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Gel-Del is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.
Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.